NCT01042925 - Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Breast CancerBreast Neoplasms

Interventions

DRUG

XL147 (SAR245408)

administered orally once daily as tablet(s)

BIOLOGICAL

trastuzumab

administered by IV once every 3 weeks

DRUG

paclitaxel

administered by IV once every week

Trial Locations (9)

Investigational Site Number 1150, New York

Investigational Site Number 1151, The Bronx

Investigational Site Number 3413, Madrid

Investigational Site Number 1238, Fort Meyers

Investigational Site Number 1214, Nashville

Investigational Site Number 1246, Nashville

Investigational Site Number 1330, Detroit

Investigational Site Number 1537, Los Angeles

Investigational Site Number 1138, Boston